NDAORALTABLET
Approved
Apr 1953
Lifecycle
LOE Approaching
Competitive Pressure
30/100
Clinical Trials
20
Data completeness
3/8 — Basic
PAMINE (methscopolamine bromide) by Sandoz is clinical pharmacology methscopolamine bromide is an anticholinergic agent which possesses most of the pharmacologic actions of that drug class. First approved in 1953.
Drug data last refreshed Yesterday
Mechanism of Action
CLINICAL PHARMACOLOGY Methscopolamine bromide is an anticholinergic agent which possesses most of the pharmacologic actions of that drug class. These include reduction in volume and total acid content of gastric secretion, inhibition of gastrointestinal motility, inhibition of salivary excretion,…
Indications
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
Clinical Trials (20)
A PET/MRI Study of Cobenfy on Dopamine Transmission in Schizophrenia
Started Jul 2026
12 enrolled
SCHIZOPHRENIA 1 (Disorder)Schizoaffecitve Disorder
Tonic Motor Activation (TOMAC) Therapy in Patients With Restless Legs Syndrome and Dopaminergic Augmentation
Started Apr 2026
50 enrolled
Restless Legs Syndrome
This Clinical Trial is Designed to Evaluate the Safety, Tolerability, Feasibility and Preliminary Efficacy of NouvNeu001 (Human Dopaminergic Progenitor Cells Injection) in Patients With Parkinson's Disease.
Started Jan 2026
5 enrolled
Parkinson Disease
Evaluation of Long-term Safety in Parkinsonian Patients With Intracerebroventricular Administration of A-dopamine (Anaerobic Dopamine)
Started Oct 2025
1 enrolled
Parkinson Disease
Study of Oral ABBV-932 Capsules to Evaluate Dopamine D2 and D3 Receptor Occupancy in Brain in Adult Healthy Volunteers
Started Aug 2024
11 enrolled
Healthy Volunteers
Worked on PAMINE at Sandoz? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.